NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $6.72 +0.11 (+1.59%) Closing price 03:59 PM EasternExtended Trading$6.48 -0.24 (-3.64%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Tevogen Bio Stock (NASDAQ:TVGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$6.35▼$6.9950-Day Range$4.41▼$7.8552-Week Range$3.64▼$39.83Volume6,534 shsAverage Volume22,303 shsMarket Capitalization$43.78 millionP/E RatioN/ADividend YieldN/APrice Target$100.00Consensus RatingReduce Company Overview Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and cancer. The company’s approach uses antigen-specific cytotoxic T lymphocytes designed to recognize and eliminate infected or abnormal cells while seeking to provide an “off-the-shelf” treatment option. Tevogen’s pipeline is built around its ExacTcell platform, which is intended to support the development and manufacturing of targeted cellular immunotherapies. Its lead program, TVGN 489, is an investigational, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19. The therapy is not approved for commercial use. Tevogen was founded by physician and biotechnology executive Dr. Ryan Saadi, who serves as the company’s chairman and chief executive officer. The company is based in Warren, New Jersey, and is developing therapies for potential use in the United States and other markets, subject to clinical development and regulatory approvals. Tevogen became a publicly traded company through a business combination with Semper Paratus Acquisition Corporation.AI Generated. May Contain Errors. Read More Tevogen Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreTVGN MarketRank™: Tevogen Bio scored higher than 35% of companies evaluated by MarketBeat, and ranked 729th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingTevogen Bio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTevogen Bio has a consensus price target of $100.00, representing about 1,387.0% upside from its current price of $6.73.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tevogen Bio is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tevogen Bio is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Tevogen Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.60% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 5.23.Change versus previous monthShort interest in Tevogen Bio has recently decreased by 2.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.91 News SentimentTevogen Bio has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tevogen Bio this week, compared to 2 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have not sold or bought any company stock.Percentage Held by Insiders65.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTevogen Bio has minimal institutional ownership at this time.Read more about Tevogen Bio's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVGN Stock News HeadlinesTevogen Regains Compliance with Nasdaq Global Market Continued Listing RequirementsSeptember 30 at 4:30 PM | globenewswire.comTevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% - Time to Buy?September 23, 2026 | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 1 at 1:00 AM | Porter & Company (Ad)Tevogen Bio Holdings Rebrands as Tevogen Inc.July 30, 2026 | tipranks.comTevogen Bio Holdings Corporate Event Calendar | NASDAQ:TVGNJuly 24, 2026 | benzinga.comTevogen Bio Announces 2026 Annual Meeting of StockholdersJuly 13, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10, 2026 | finanznachrichten.deTevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9, 2026 | quiverquant.comQSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $16.5550 at the beginning of 2026. Since then, TVGN stock has decreased by 59.4% and is now trading at $6.7250. How were Tevogen Bio's earnings last quarter? Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its quarterly earnings results on Friday, August, 14th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.53) by $1.01. When did Tevogen Bio's stock split? Tevogen Bio's stock reverse split on Friday, March 6th 2026.The 1-50 reverse split was announced on Wednesday, March 4th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tevogen Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tevogen Bio investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings8/14/2026Today10/01/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TVGN's financial health is in the Green zone, according to TradeSmith. TVGN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CIK1860871 Webwww.tevogen.com Phone(646) 807-8832FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Tevogen Bio$100.00 High Price Target$100.00 Low Price Target$100.00 Potential Upside/Downside+1,387.0%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.27 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-468.32% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($211.84) per share Price / Book-0.03Miscellaneous Outstanding Shares6,510,000Free Float2,240,000Market Cap$43.78 million OptionableN/A Beta0.17 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TVGN) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
